A091401: Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients with Metastatic or Unresectable Sarcoma
Aims: The purpose of this study is to see the good and bad effects of study drugs Nivolumab and/or ipilimumab in treating sarcoma.
Principal Investigator: Bruce Brockstein, MD
IRB Approval Number: EH15-366
Sponsor: Alliance for Clinical Trials in Oncology
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes